Pharmaceutical industry representatives in Washington are scrambling to measure the damage Robert F. Kennedy Jr. might inflict on the FDA.

WASHINGTON — Robert F. Kennedy Jr., President-elect Trump’s nominee for Secretary of Health and Human Services, has ...

Anxious and bewildered, some drugmakers are reaching out to their lobbyists about how Robert Kennedy’s pending nomination ...

Kennedy has a history of vaccine disinformation and suggested a ban on fluoride in water and eliminating entire FDA ...

Processed foods are in the cross hairs of Robert F. Kennedy Jr., but battling major companies could collide with ...

The FDA spent more than 15 years crafting the guidelines, which are designed to do away with industry practices that downplay ...

Wolfe projects a positive outlook for Pharma & Large-Cap Biotech stocks despite potential policy changes as part of Make America Healthy Again movement. Read more here.

Shares in several pharmaceutical and biotechnology companies have fallen since President-elect Trump announced Thursday that ...

Pfizer's drug approvals and advertising revenue could be affected by RFK Jr.'s potential appointment. See why PFE stock is a ...

Critics believe Donald Trump's nominee to lead Health and Human Services poses a threat to the achievements of a ...

Why one trial participant's healthy birth after her CAR-T treatment for lupus is catching resesarchers' attention: ...